WallStreetZenWallStreetZen

NASDAQ: ESLA
Estrella Immunopharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their ESLA stock forecasts and price targets.

Forecast return on equity

Is ESLA forecast to generate an efficient return?

Company
-901.53%
Industry
21.83%
Market
168.15%
ESLA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ESLA forecast to generate an efficient return on assets?

Company
3,671.62%
Industry
23.8%
ESLA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ESLA earnings per share forecast

What is ESLA's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.26
Avg 2 year Forecast
-$32.64
Avg 3 year Forecast
-$0.33

ESLA revenue forecast

What is ESLA's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

ESLA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ESLA$0.47N/AN/A
KRSA$30.49$56.50+85.31%Strong Buy
PLRZ$9.61N/AN/A
ICU$4.69$8.00+70.58%Strong Buy
ACTU$0.82$10.50+1,182.05%Strong Buy
View Top Biotech Stocks

Estrella Immunopharma Stock Forecast FAQ

What is ESLA's earnings growth forecast for 2026-2027?

(NASDAQ: ESLA) Estrella Immunopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.53%.

Estrella Immunopharma's earnings in 2026 is -$10,012,726.On average, 3 Wall Street analysts forecast ESLA's earnings for 2026 to be -$11,091,955, with the lowest ESLA earnings forecast at -$10,656,977, and the highest ESLA earnings forecast at -$11,418,189. On average, 3 Wall Street analysts forecast ESLA's earnings for 2027 to be -$1,419,770,281, with the lowest ESLA earnings forecast at -$1,364,093,015, and the highest ESLA earnings forecast at -$1,461,528,230.

In 2027, ESLA is forecast to generate -$14,197,703 in earnings, with the lowest earnings forecast at -$13,640,930 and the highest earnings forecast at -$14,615,282.

If you're new to stock investing, here's how to buy Estrella Immunopharma stock.

What is ESLA's revenue growth forecast for 2026-2027?

(NASDAQ: ESLA) Estrella Immunopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.51%.

Estrella Immunopharma's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast ESLA's revenue for 2026 to be $0, with the lowest ESLA revenue forecast at $0, and the highest ESLA revenue forecast at $0. On average, 3 Wall Street analysts forecast ESLA's revenue for 2027 to be $0, with the lowest ESLA revenue forecast at $0, and the highest ESLA revenue forecast at $0.

In 2027, ESLA is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ESLA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ESLA) forecast ROA is 3,671.62%, which is higher than the forecast US Biotechnology industry average of 23.8%.

What is ESLA's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: ESLA) Estrella Immunopharma's current Earnings Per Share (EPS) is -$0.24. On average, analysts forecast that ESLA's EPS will be -$0.26 for 2026, with the lowest EPS forecast at -$0.25, and the highest EPS forecast at -$0.26. On average, analysts forecast that ESLA's EPS will be -$32.64 for 2027, with the lowest EPS forecast at -$31.36, and the highest EPS forecast at -$33.60. In 2027, ESLA's EPS is forecast to hit -$0.33 (min: -$0.31, max: -$0.34).

What is ESLA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ESLA) forecast ROE is -901.53%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.